Buchumschlag

Large collaborative registries and real-world data to manage amyloid-related imaging abnormalities

To the Editor Hall et al describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Piazza, Fabrizio (VerfasserIn) , Frölich, Lutz (VerfasserIn) , Padovani, Alessandro (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: April 25, 2022
In: JAMA neurology
Year: 2022, Jahrgang: 79, Heft: 6, Pages: 633-634
ISSN:2168-6157
DOI:10.1001/jamaneurol.2022.0731
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamaneurol.2022.0731
Verlag, lizenzpflichtig, Volltext: https://jamanetwork.com/journals/jamaneurology/fullarticle/2791266
Volltext
Verfasserangaben:Fabrizio Piazza, Lutz Frölich, Alessandro Padovani
Beschreibung
Zusammenfassung:To the Editor Hall et al describe a patient with prodromal Alzheimer disease who developed 6 relapsing episodes of amyloid-related imaging abnormality edema (ARIA-E) over 44 months of treatment within the aducanumab long-term extension period. Together with the recently reported 41.3% risk of ARIA in the Phase 3 Study of Aducanumab in Early Alzheimer’s Disease (EMERGE and ENGAGE) trials, we believe this work is of particular interest as it points out ARIA as a timely research and clinical priority, prompting the urgent need to define standardized guidelines for the treatment and follow-up monitoring of such side events.
Beschreibung:Gesehen am 05.02.2024
Beschreibung:Online Resource
ISSN:2168-6157
DOI:10.1001/jamaneurol.2022.0731

Ähnliche Einträge